查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2002691

体内CRO市场：按类型、服务类型、模式、适应症和最终用户划分－2026-2032年全球市场预测

In Vivo CRO Market by Type, Service Type, Modality, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，体内 CRO 市场价值将达到 65.8 亿美元，到 2026 年将成长至 72.1 亿美元，到 2032 年将达到 128.8 亿美元，年复合成长率为 10.06%。

主要市场统计数据
基准年 2025 65.8亿美元
预计年份：2026年 72.1亿美元
预测年份：2032年 128.8亿美元
复合年增长率 (%) 10.06%

策略实施概述了塑造当今体内CRO的不断演变的优先事项和营运动态

体内合约研究领域处于科学复杂性和操作严谨性的交汇点，转化准确性和合规性对于专案的持续进行至关重要。随着申办方致力于生技药品、基因疗法和新一代治疗方法的研发，对可靠的临床前模型和一体化服务管道的需求日益增长。为此，各机构正在重组，以更快地提供更高品质的数据，同时确保符合日益严格的动物福利和生物安全标准。

分析正在重塑 In Vivo 合约研究服务营运、技术和监管预期的变革性变化。

该领域正经历一系列相互交织的变革，这些变革正在重塑研究的设计、进行和解读方式。首先，成像、遥测和体内生物标记技术的成熟，使得更丰富、更具转化价值的数据集得以生成，从而减少了对单一终点研究的依赖，并促进了纵向研究设计。其次，生技药品和基因编辑技术的进步带来了新的安全考量，需要製定量身定制的毒理学策略并对设施进行改造，以安全地应对这些复杂性。

彙编了关于 2025 年美国关税政策变化对生物研究提供者的供应链、成本结构和战略运营的影响的定性评估。

美国2025年关税政策的转变，使得整个生物研究生态系对供应链韧性的关注日益提高。专业耗材、设备零件以及某些动物饲养用品的采购通常依赖全球采购，而关税调整会给采购计画带来不确定性。因此，供应商正在重新评估供应商所在地，寻找替代供应商，并建立库存缓衝，以确保检验的连续性。这些应对措施优先考虑冗余备份和经过验证的替代供应商，以减少中断。

深入的細項分析揭示了能力深度、模式专业化以及与最终用户的关係如何为整个生物医​​学研究市场提供明显的竞争优势。

差异化始于生物模型的专业化。按非囓齿类和囓齿类模型类型进行细分，会造成设施需求、兽医专业知识和监管管道方面的差异。在非囓齿类模型方面拥有丰富经验的机构通常在复杂的外科手术能力和长期药物动力学监测方面表现出色，而囓齿类模型方面的专业知识则支持高性能筛检和早期概念验证(PoC) 工作。同时，服务类型的细分——从临床服务和咨询策略到实验室服务、临床前服务、监管服务以及毒性和安全性评估——在咨询服务提供者和以执行为导向的供应商之间划清了界限。将咨询服务与实践性毒性测试和符合良好实验室规范 (GLP) 的实验室服务相结合的公司，能够提供差异化服务，从而减少转化研究的阻力。

区域洞察揭示了地理趋势、法规结构和人才生态系统如何影响全球主要区域的需求、产能分布和伙伴关係模式。

地理环境对商业模式和策略重点有显着影响。在美洲，清晰的监管环境、完善的GLP基础设施以及与主要申办公司总部的接近性，为复杂且高度合规的项目提供了支持，并促进了申办方与CRO之间的频繁合作。这种环境有利于拥有健全的品管体系，并能依照IND/CTA申报要求进行后期临床前包装的供应商。相较之下，欧洲、中东和非洲的管理体制和研究生态系统各不相同，区域协调努力与区域特定的合规要求并存。这些地区的供应商通常优先考虑柔软性、跨司法管辖区的经验以及与学术机构的合作以获得专业知识。在跨国计画中，人才招募和跨境物流是关键的考量。

本报告深入分析了企业能力和策略行动，展示了领导企业、专业公司和新兴参与企业如何透过投资、伙伴关係和卓越营运来提升自身竞争力。

领先机构正在展现出能够带来竞争优势的能力建构和协作模式。首先，对平台技术和检验工作流程的投资能够提高可重复性，缩短营运週期，并最终支援更复杂的专案。其次，将咨询、测试设计和法规联络服务与良好实验室规范 (GLP) 实施相结合的公司能够创造无缝的客户体验并降低转换风险。第三，与学术机构、仪器製造商和专业实验室建立策略伙伴关係，能够在不产生大量固定成本的情况下利用专业领域的专长，从而使申办方能够获得灵活的资源。

为帮助产业领导者增强韧性、提高转换保真度、加速临床前开发阶段的专案决策，提供切实可行的优先建议。

首先，优先投资于检验的平台技术和资料系统，以确保资料集的可重复性和可审计性，并支援不同测试之间的比较。这有助于减少下游流程的不确定性，并增强监管机构的信心。其次，透过咨询型测试设计服务，加强与申办者的上游合作，使临床前终点与临床目标一致。这种合作方式可以降低测试设计修改的风险，并缩短开发週期。第三，透过供应商多元化和协商灵活的采购条款，降低供应链中断和政策变化带来的风险。确保有备选供应商并维持充足的库存缓衝，可以在不大幅增加固定成本的情况下保障业务永续营运。

本文檔概述了用于在生物研究领域得出严谨且可操作的见解的资料来源、分析框架和检验程序，展示了高度透明的调查方法。

本分析整合了多方面的证据，以得出平衡且检验的结论。主要资讯来源包括对行业领导者、兽医病理学和毒理学专家以及负责临床前开发的高级专案主管的结构化访谈。这些定性对话深入探讨了营运挑战、能力投资和伙伴关係重点。为补充主要研究，我们还系统地回顾了监管指南、同行评审的科学文献和公共公告，以提供有关合规趋势、新兴模型系统和动物福利标准的背景资讯。

一份权威的综合分析报告，重点阐述了将决定活检提供者和赞助商专案成败的策略挑战和营运重点。

大量证据表明，生物医学研究中最关键的差异化因素在于可重复资料的产生、综合咨询服务以及稳健的营运网络。能够将咨询式测试设计、检验的实施平台和严格的品管系统结合的供应商，最能应对复杂的试验模式和特定适应症的需求。同时，申办方也能从选择能够预见监管预期、应对供应链波动并提供透明且可审计的数据集的合作伙伴中获益匪浅，从而加快审查和决策进程。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：体内CRO市场：依类型划分

  • 不囓齿类动物
  • 囓齿动物

第九章：体内CRO市场：依服务类型划分

  • 临床服务
  • 咨询策略
  • 检查服务
  • 临床前服务
  • 监管服务
  • 毒性和安全性评估

第十章：体内CRO市场：依模式划分

  • 聚合物化合物
  • 低分子化合物

第十一章 体内CRO市场：依适应症划分

  • 心血管疾病
    • 冠状动脉疾病
    • 心臟衰竭
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染疾病
  • 神经系统疾病
    • 神经退化性疾病
    • 精神疾病
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固体癌
  • 呼吸系统疾病
    • 气喘
    • 慢性阻塞性肺病

第十二章 体内CRO市场：依最终用户划分

  • 学术和研究机构
  • 政府和监管机构
  • 医疗设备製造商
  • 製药和生物技术公司

第十三章 体内CRO市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 体内CRO市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 体内CRO市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国体内CRO市场

第十七章：中国体内CRO市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Altogen Labs
  • Biocytogen Boston Corp.
  • Cellvax, SAS
  • Charles River Laboratories International, Inc.
  • Crown Bioscience, Inc.
  • Eurofins Scientific SE
  • Evotec SE
  • Explicyte（Immusmol SAS Company）
  • GEMPHARMATECH LLC
  • ICON Plc
  • Imavita SAS
  • IQVIA Holdings Inc.
  • IVRS AB
  • JSR Corporation
  • Labcorp Drug Development PRIVATE LIMITED
  • Medpace, Inc.
  • Melior Discovery Inc.
  • Noble Life Sciences Inc.
  • Parexel International Corporation
  • Pharmacology Discovery Services Ltd.
  • Pharmaron Beijing Co., Ltd.
  • Pharmatest Services Ltd.
  • PPD Inc.（Thermo Fisher Scientific, Inc.）
  • PSI CRO AG
  • Syneos Health Inc.
  • Syngene International Limited
  • Taconic Biosciences, Inc.
  • WuXi AppTec, Inc.
  • Yecuris Corporation
Product Code: MRR-0D217D5AEEAC

The In Vivo CRO Market was valued at USD 6.58 billion in 2025 and is projected to grow to USD 7.21 billion in 2026, with a CAGR of 10.06%, reaching USD 12.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.58 billion
Estimated Year [2026] USD 7.21 billion
Forecast Year [2032] USD 12.88 billion
CAGR (%) 10.06%

Strategic introduction framing the evolving priorities and operational dynamics shaping in vivo contract research organizations today

The in vivo contract research landscape sits at the intersection of scientific complexity and operational rigor, where translational fidelity and regulatory alignment determine program continuity. As sponsors pursue biologics, gene therapies, and next-generation modalities, demand for robust preclinical models and integrated service pathways has intensified. In response, organizations are reconfiguring capabilities to deliver higher quality data with faster turnarounds while maintaining compliance with tightening animal welfare and biosafety standards.

Moreover, cross-functional collaboration between preclinical teams, toxicologists, and regulators has become a central operational philosophy. This alignment supports more predictable study designs and smoother handoffs into clinical development. Consequently, leading providers are investing in platform technologies, data integrity protocols, and personnel training to sustain reproducibility and traceability across study lifecycles.

Transitioning from historical silos to integrated service models, the sector now prioritizes end-to-end solutions that reduce translational risk. Stakeholders evaluating partnerships increasingly favor providers who combine deep in vivo expertise with consultative design capabilities, regulatory acumen, and a demonstrable track record of quality systems.

Analysis of transformative shifts rewriting operational, technological, and regulatory expectations across in vivo contract research services

The sector is undergoing a set of converging shifts that are reshaping how studies are designed, executed, and interpreted. First, technological maturation in imaging, telemetry, and in vivo biomarkers enables richer, more translational datasets, reducing the reliance on single-endpoint studies and encouraging longitudinal designs. Second, advances in biologic modalities and gene editing have introduced novel safety considerations that require bespoke toxicology strategies and facility adaptations to manage complexity safely.

Concurrently, regulatory agencies worldwide are harmonizing expectations around data integrity, animal welfare, and study reproducibility. These policy movements increase the emphasis on GLP-grade operations, validated systems, and transparent data capture. As a result, providers must demonstrate rigorous quality systems and invest in staff competencies to remain competitive.

Finally, commercial dynamics are shifting toward collaborative development models where sponsors, CROs, and academic partners coordinate earlier and more closely. This collaborative posture accelerates decision cycles and reduces costly rework. Taken together, these trends are elevating the role of consultative CRO partners who can integrate experimental design, execution excellence, and regulatory foresight into cohesive programs.

Cumulative qualitative assessment of how evolving United States tariff policies in 2025 influence supply chains, cost structures, and strategic operations for in vivo research providers

Shifts in U.S. tariff policies in 2025 have amplified attention on supply chain resilience across the in vivo research ecosystem. Procurement of specialized consumables, equipment components, and certain animal husbandry supplies often relies on global sourcing, and tariff adjustments introduce uncertainty into procurement planning. Consequently, providers are reassessing supplier footprints, seeking alternative vendors, and building inventory buffers to maintain study continuity. These operational responses prioritize redundancy and validated secondary suppliers to mitigate disruption.

In addition to direct cost pressures, tariffs reshuffle comparative advantages between domestic manufacturing and imported goods, influencing capital investment decisions for facility upgrades and local production capabilities. In response, some organizations accelerate capital projects that reduce foreign dependence, while others pursue contracting terms and hedging strategies to insulate programs from near-term price volatility. Furthermore, tariff dynamics ripple through contract structuring, prompting more explicit pass-through clauses and renegotiation frameworks to allocate commercial risk between sponsors and providers.

Overall, the supply chain and commercial planning implications of tariff policy changes underscore the importance of proactive procurement strategies, diversified supplier ecosystems, and contractual clarity to preserve schedule integrity and research continuity.

Insightful segmentation analysis revealing where capability depth, modality focus, and end-user relationships create distinct competitive advantages across the in vivo research market

Differentiation begins with biological model specialization: Type segmentation between Non-Rodent and Rodent models drives variations in facility requirements, veterinary expertise, and regulatory pathways. Organizations with deep experience in non-rodent models often command complex surgical capabilities and extended pharmacokinetic monitoring, while rodent expertise supports high-throughput screening and early proof-of-concept work. In parallel, service type segmentation-ranging from Clinical Services and Consulting & Strategy to Laboratory Services, Preclinical Services, Regulatory Services, and Toxicological & Safety Assessment-creates clear lines between consultative providers and execution-focused vendors. Firms that combine consulting with hands-on toxicology and GLP laboratory services create differentiated offerings that reduce translational friction.

Modality focus between Large Molecules and Small Molecules further shapes operational design; biologics demand specific handling, immunogenicity assessment, and dosing paradigms, whereas small molecule programs emphasize ADME characterization and metabolic profiling. Indication segmentation across Cardiovascular Diseases, Infectious Diseases, Neurological Disorders, Oncology, and Respiratory Disorders introduces therapeutic-area specific model needs and endpoint complexity. Within indications, subcategories such as coronary artery disease and heart failure, bacterial and viral infections, neurodegenerative and psychiatric disorders, hematological malignancies and solid tumors, and asthma and COPD require tailored endpoints, disease modeling expertise, and specialized pathology capabilities. Finally, end-user segmentation encompassing Academic & Research Institutions, Government & Regulatory Organizations, Medical Device Companies, and Pharmaceuticals & Biotechnology Companies determines project cadence, compliance expectations, and reporting depth. Sponsors from academic settings often prioritize exploratory flexibility, whereas industry and regulatory customers demand higher documentation rigor and predictable timelines.

Regional insights that clarify how geographic dynamics, regulatory frameworks, and talent ecosystems influence demand, capability distribution, and partnership models across major global territories

Geographic context significantly shapes operational models and strategic priorities. In the Americas, regulatory clarity, established GLP infrastructure, and proximity to major sponsor headquarters support complex, high-compliance programs and facilitate frequent sponsor-CRO interaction. This environment favors providers with strong quality management systems and capabilities to run late-stage preclinical packages that align closely with IND/CTA submissions. Conversely, Europe, Middle East & Africa present a mosaic of regulatory regimes and research ecosystems where regional harmonization initiatives coexist with localized compliance requirements. Providers in this region often emphasize flexibility, multi-jurisdictional experience, and collaborations with academic centers to access specialized expertise. Talent availability and cross-border logistics are key considerations for multinational programs.

Asia-Pacific offers a rapidly expanding base of research capacity, driven by investments in laboratory infrastructure, growing local pharmaceutical industries, and cost competitiveness for certain services. However, sponsors and providers navigating this region must account for variable regulatory expectations, differences in animal welfare practices, and logistical complexity. As a result, cross-regional programs typically rely on strong governance models and centralized data standards to ensure consistency. Collectively, these regional dynamics influence where providers invest, how they structure global networks, and which partnership models best support sponsor objectives.

Company capability and strategic behavior insights that indicate how leaders, specialists, and emerging entrants create competitive differentiation through investments, partnerships, and operational excellence

Leading organizations demonstrate patterns of capability building and collaboration that translate into competitive advantage. First, investment in platform technologies and validated workflows enhances reproducibility and shortens operational cycles, which in turn supports higher-complexity programs. Second, firms that integrate consulting, study design, and regulatory liaison services with GLP execution create a seamless client experience that reduces translational risk. Third, strategic partnerships with academic centers, instrumentation providers, and specialty labs enable access to niche expertise without the full fixed-cost investment, facilitating flexible resourcing for sponsors.

Additionally, successful providers emphasize talent development and cross-disciplinary teams that combine veterinary medicine, pathology, pharmacology, and data science. This multidisciplinary approach improves endpoint selection, data interpretation, and risk mitigation. Finally, companies pursuing geographic diversification leverage regional strengths-such as specialized disease model expertise or cost-effective operational nodes-to create resilient delivery networks. Together, these behaviors highlight the routes by which companies scale capability while managing scientific and commercial risk.

Practical, prioritized recommendations that enable industry leaders to strengthen resilience, improve translational fidelity, and accelerate program decision-making across preclinical development

First, prioritize investment in validated platform technologies and data systems that ensure reproducible, auditable datasets and support cross-study comparisons. Doing so reduces downstream ambiguity and enhances regulatory confidence. Second, build stronger upstream engagement with sponsors through consultative study design services that align preclinical endpoints with clinical objectives; this collaborative stance reduces redesign risk and shortens development cycles. Third, diversify supplier footprints and negotiate flexible procurement terms to mitigate exposure to supply chain shocks and policy changes. Implementing secondary sourcing and targeted inventory buffers supports continuity without unduly raising fixed costs.

Fourth, enhance workforce capabilities by cross-training staff in contemporary modalities, welfare standards, and GLP practices, thereby increasing operational agility. Fifth, formalize partnership models with academic centers and specialty labs to access niche expertise while maintaining core operational focus. Finally, update commercial contracts to clarify cost escalation mechanisms and risk allocation in the face of tariff or logistic volatility. These prioritized actions combine to increase resilience, improve translational alignment, and protect program timelines.

Transparent research methodology outlining data sources, analytical frameworks, and validation steps used to develop rigorous, actionable insights for the in vivo research sector

This analysis synthesizes multiple evidence streams to ensure balanced and verifiable conclusions. Primary inputs include structured interviews with industry leaders, subject matter experts in veterinary pathology and toxicology, and senior program directors responsible for preclinical development. These qualitative engagements informed perspectives on operational challenges, capability investments, and partnership priorities. Complementing primary research, a systematic review of regulatory guidance, peer-reviewed scientific literature, and public policy announcements provided context on compliance trends, emerging model systems, and welfare standards.

Analytical methods incorporated thematic coding of qualitative data and cross-case comparison to identify recurring patterns and divergent practices. Validation occurred through triangulation across sources and targeted follow-up discussions to resolve inconsistencies. Throughout, emphasis was placed on procedural transparency, careful attribution of inferential leaps, and clear articulation of assumptions. The methodology balances depth of practitioner insight with a robust review of publicly available technical and regulatory material to deliver credible, actionable findings.

Conclusive synthesis emphasizing the strategic imperatives and operational priorities that will determine program success for in vivo research providers and sponsors alike

The cumulative evidence indicates that the most consequential differentiators in in vivo research will be reproducible data generation, integrated advisory services, and resilient operational networks. Providers that blend consultative study design, validated execution platforms, and disciplined quality systems will be best positioned to support complex modalities and indication-specific requirements. Simultaneously, sponsors benefit from choosing partners who can anticipate regulatory expectations, manage supply chain variability, and deliver transparent, auditable datasets that accelerate reviews and decisions.

Looking forward, organizations that invest in multidisciplinary talent, platform validation, and flexible partnerships will reduce translational uncertainty and maintain program cadence in the face of external disruptions. In short, strategic focus on quality, collaboration, and resilience will differentiate leaders and enable more predictable progression from preclinical insights to clinical milestones.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. In Vivo CRO Market, by Type

  • 8.1. Non-Rodent
  • 8.2. Rodent

9. In Vivo CRO Market, by Service Type

  • 9.1. Clinical Services
  • 9.2. Consulting & Strategy
  • 9.3. Laboratory Services
  • 9.4. Preclinical Services
  • 9.5. Regulatory Services
  • 9.6. Toxicological & Safety Assessment

10. In Vivo CRO Market, by Modality

  • 10.1. Large Molecules
  • 10.2. Small Molecules

11. In Vivo CRO Market, by Indication

  • 11.1. Cardiovascular Diseases
    • 11.1.1. Coronary Artery Disease
    • 11.1.2. Heart Failure
  • 11.2. Infectious Diseases
    • 11.2.1. Bacterial Infections
    • 11.2.2. Viral Infections
  • 11.3. Neurological Disorders
    • 11.3.1. Neurodegenerative Disorders
    • 11.3.2. Psychiatric Disorders
  • 11.4. Oncology
    • 11.4.1. Hematological Malignancies
    • 11.4.2. Solid Tumors
  • 11.5. Respiratory Disorders
    • 11.5.1. Asthma
    • 11.5.2. Chronic Obstructive Pulmonary Disease

12. In Vivo CRO Market, by End User

  • 12.1. Academic & Research Institutions
  • 12.2. Government & Regulatory Organizations
  • 12.3. Medical Device Companies
  • 12.4. Pharmaceuticals & Biotechnology Companies

13. In Vivo CRO Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. In Vivo CRO Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. In Vivo CRO Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States In Vivo CRO Market

17. China In Vivo CRO Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Altogen Labs
  • 18.6. Biocytogen Boston Corp.
  • 18.7. Cellvax, SAS
  • 18.8. Charles River Laboratories International, Inc.
  • 18.9. Crown Bioscience, Inc.
  • 18.10. Eurofins Scientific SE
  • 18.11. Evotec SE
  • 18.12. Explicyte by Immusmol SAS Company
  • 18.13. GEMPHARMATECH LLC
  • 18.14. ICON Plc
  • 18.15. Imavita S.A.S.
  • 18.16. IQVIA Holdings Inc.
  • 18.17. IVRS AB
  • 18.18. JSR Corporation
  • 18.19. Labcorp Drug Development PRIVATE LIMITED
  • 18.20. Medpace, Inc.
  • 18.21. Melior Discovery Inc.
  • 18.22. Noble Life Sciences Inc.
  • 18.23. Parexel International Corporation
  • 18.24. Pharmacology Discovery Services Ltd.
  • 18.25. Pharmaron Beijing Co., Ltd.
  • 18.26. Pharmatest Services Ltd.
  • 18.27. PPD Inc. by Thermo Fisher Scientific, Inc.
  • 18.28. PSI CRO AG
  • 18.29. Syneos Health Inc.
  • 18.30. Syngene International Limited
  • 18.31. Taconic Biosciences, Inc.
  • 18.32. WuXi AppTec, Inc.
  • 18.33. Yecuris Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL IN VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IN VIVO CRO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IN VIVO CRO MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IN VIVO CRO MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IN VIVO CRO MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IN VIVO CRO MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IN VIVO CRO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IN VIVO CRO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IN VIVO CRO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IN VIVO CRO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES IN VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA IN VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IN VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IN VIVO CRO MARKET SIZE, BY NON-RODENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IN VIVO CRO MARKET SIZE, BY NON-RODENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IN VIVO CRO MARKET SIZE, BY NON-RODENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IN VIVO CRO MARKET SIZE, BY RODENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IN VIVO CRO MARKET SIZE, BY RODENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IN VIVO CRO MARKET SIZE, BY RODENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IN VIVO CRO MARKET SIZE, BY CLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IN VIVO CRO MARKET SIZE, BY CLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IN VIVO CRO MARKET SIZE, BY CLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IN VIVO CRO MARKET SIZE, BY CONSULTING & STRATEGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IN VIVO CRO MARKET SIZE, BY CONSULTING & STRATEGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IN VIVO CRO MARKET SIZE, BY CONSULTING & STRATEGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IN VIVO CRO MARKET SIZE, BY LABORATORY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IN VIVO CRO MARKET SIZE, BY LABORATORY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IN VIVO CRO MARKET SIZE, BY LABORATORY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN VIVO CRO MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IN VIVO CRO MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IN VIVO CRO MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IN VIVO CRO MARKET SIZE, BY REGULATORY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IN VIVO CRO MARKET SIZE, BY REGULATORY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IN VIVO CRO MARKET SIZE, BY REGULATORY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IN VIVO CRO MARKET SIZE, BY TOXICOLOGICAL & SAFETY ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IN VIVO CRO MARKET SIZE, BY TOXICOLOGICAL & SAFETY ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IN VIVO CRO MARKET SIZE, BY TOXICOLOGICAL & SAFETY ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IN VIVO CRO MARKET SIZE, BY LARGE MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IN VIVO CRO MARKET SIZE, BY LARGE MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IN VIVO CRO MARKET SIZE, BY LARGE MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IN VIVO CRO MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN VIVO CRO MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IN VIVO CRO MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IN VIVO CRO MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IN VIVO CRO MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IN VIVO CRO MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IN VIVO CRO MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IN VIVO CRO MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IN VIVO CRO MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IN VIVO CRO MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IN VIVO CRO MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IN VIVO CRO MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IN VIVO CRO MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IN VIVO CRO MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IN VIVO CRO MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IN VIVO CRO MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IN VIVO CRO MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IN VIVO CRO MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IN VIVO CRO MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IN VIVO CRO MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IN VIVO CRO MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IN VIVO CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IN VIVO CRO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IN VIVO CRO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IN VIVO CRO MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IN VIVO CRO MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IN VIVO CRO MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IN VIVO CRO MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IN VIVO CRO MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IN VIVO CRO MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IN VIVO CRO MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IN VIVO CRO MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IN VIVO CRO MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IN VIVO CRO MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IN VIVO CRO MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IN VIVO CRO MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IN VIVO CRO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IN VIVO CRO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IN VIVO CRO MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IN VIVO CRO MARKET SIZE, BY GOVERNMENT & REGULATORY ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IN VIVO CRO MARKET SIZE, BY GOVERNMENT & REGULATORY ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IN VIVO CRO MARKET SIZE, BY GOVERNMENT & REGULATORY ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IN VIVO CRO MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IN VIVO CRO MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IN VIVO CRO MARKET SIZE, BY MEDICAL DEVICE COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IN VIVO CRO MARKET SIZE, BY PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IN VIVO CRO MARKET SIZE, BY PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IN VIVO CRO MARKET SIZE, BY PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IN VIVO CRO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS IN VIVO CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL IN VIVO CRO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. GCC IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 204. GCC IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. GCC IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 206. GCC IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 207. GCC IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 208. GCC IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. GCC IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. G7 IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. G7 IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 237. G7 IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 238. G7 IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 239. G7 IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 240. G7 IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 241. G7 IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. G7 IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. NATO IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. NATO IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. NATO IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 248. NATO IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 249. NATO IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 250. NATO IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 251. NATO IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 252. NATO IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. NATO IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL IN VIVO CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES IN VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA IN VIVO CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA IN VIVO CRO MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA IN VIVO CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA IN VIVO CRO MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA IN VIVO CRO MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA IN VIVO CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA IN VIVO CRO MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA IN VIVO CRO MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA IN VIVO CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA IN VIVO CRO MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA IN VIVO CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)